bluebird bio Inc. (accounting case)

Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of bluebird bio Inc. (NASDAQ: BLUE) resulting from allegations that bluebird may have issued materially misleading business information to the investing public.

If you purchased bluebird securities and would like to join the prospective action, please click “Join This Class Action.”

If you purchased bluebird securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.


On March 26, 2024, before the market opened, bluebird filed an 8-K with the SEC in which it announced, “[o]n March 24, 2024, the Audit Committee of the Board of Directors (the “Audit Committee”) of the Company, based on the recommendation of management and after consultation with EY, concluded that the Company’s previously-issued audited consolidated financial statements for each fiscal year beginning January 1, 2019 and its previously-issued unaudited interim condensed consolidated financial statements for each of the first three quarters in such years, as well as the associated earnings releases and investor presentations or other communications describing such financial statements, were materially misstated and, accordingly, should no longer be relied upon.”

On this news, bluebird’s stock fell $0.16 per share, or 11.8%, to close at $1.20 per share on March 26, 2024.

公司名称: bluebird bio Inc.
股票代号: BLUE
集体诉讼期: N/A
法院: N/A


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。